What is the recommended diagnostic workup and treatment plan for interstitial cystitis (painful bladder syndrome)?

Interstitial Cystitis/Bladder Pain Syndrome: Diagnostic Workup and Treatment

Diagnostic Approach

Interstitial cystitis/bladder pain syndrome (IC/BPS) is diagnosed clinically through history, physical examination, and laboratory testing to document characteristic symptoms and exclude mimicking conditions, with cystoscopy reserved specifically for patients suspected of having Hunner lesions. 1

Essential Diagnostic Criteria

• Symptoms must be present for at least 6 weeks with documented negative urine cultures 1
• Document the following specific parameters:
  • Number of voids per day and sensation of constant urge to void 1
  • Location, character, and severity of pain, pressure, or discomfort 1
  • Dyspareunia, dysuria, ejaculatory pain in men 1
  • Relationship of pain to menstruation in women 1

Required Clinical Evaluation

• Brief neurological examination to rule out occult neurologic problems 1
• Evaluation for incomplete bladder emptying to rule out occult retention 1
• Urine culture even with negative urinalysis to detect lower bacterial levels not identifiable by dipstick 1
• Proper hematuria workup in patients with un-evaluated hematuria or tobacco exposure given high bladder cancer risk in smokers 1
• At minimum, a one-day voiding log to establish low-volume frequency voiding pattern characteristic of IC/BPS 1

Role of Cystoscopy

Cystoscopy should be performed only in patients suspected of having Hunner lesions, as this is the only consistent cystoscopic finding diagnostic for IC/BPS. 1

• Hunner lesions are the only agreed-upon cystoscopic finding that leads to diagnosis 1
• Early cystoscopic diagnosis is recommended for suspected Hunner lesions without requiring failure of other treatments first 1
• Routine cystoscopy for every IC/BPS patient is not advisable 1
• Cystoscopy is indicated when clinical mimics (bladder cancer, stones, foreign bodies) are suspected 1

Urodynamics

Urodynamics are not recommended for routine clinical use to establish IC/BPS diagnosis. 1 Specific indications include:

• Suspicion of outlet obstruction in either sex 1
• Possibility of poor detrusor contractility 1
• Refractory patients to explain lack of response to behavioral or medical therapies 1

Baseline Symptom Documentation

Establish baseline voiding symptoms and pain levels using validated instruments to measure subsequent treatment effects. 1

• Use Genitourinary Pain Index (GUPI), Interstitial Cystitis Symptom Index (ICSI), or Visual Analog Scale (VAS) 1

Treatment Algorithm

Treatment should begin with behavioral/non-pharmacologic interventions, followed by oral medications, with the understanding that IC/BPS requires multimodal therapy and no single treatment is effective for the majority of patients. 1 The 2022 AUA guidelines no longer use tiered treatment lines, emphasizing individualized concurrent therapies 1

Initial Management: Behavioral and Non-Pharmacologic Treatments

All patients should receive education about IC/BPS being a chronic disorder with symptom exacerbations and remissions, requiring trials of multiple therapeutic options before achieving acceptable symptom control. 1

Self-Care and Behavioral Modifications 1

• Fluid management: Alter urine concentration/volume through fluid restriction or additional hydration 1
• Dietary modifications: Avoid common bladder irritants; use elimination diet to identify trigger foods 1
• Over-the-counter products: Nutraceuticals, calcium glycerophosphates, phenazopyridine 1
• Physical techniques: Heat or cold application over bladder or perineum 1
• Flare-up management strategies: Meditation, imagery 1
• Pelvic floor muscle relaxation and bladder training with urge suppression 1
• Avoid symptom-worsening behaviors: Certain exercises (pelvic floor muscle exercises), tight-fitting clothing, manage constipation 1

Stress Management

Patients should implement stress management practices to improve coping techniques and manage stress-induced symptom exacerbations. 1 Psychological stress is associated with heightened pain sensitivity in IC/BPS patients 1

Oral Pharmacologic Treatments

A multimodal approach combining pharmacologic agents with other therapies is most effective; pain management alone does not constitute sufficient treatment. 1 Non-opioid alternatives should be used preferentially, with judicious use of chronic opioids only after informed shared decision-making 1

Amitriptyline (Grade B Evidence)

Amitriptyline is superior to placebo for improving IC/BPS symptoms but has common adverse effects that can compromise quality of life. 1

• Start at low doses (10 mg) and titrate gradually to 75-100 mg if tolerated 1
• Common adverse effects: sedation, drowsiness, nausea (not life-threatening) 1

Pentosan Polysulfate (Grade B Evidence)

Pentosan polysulfate (PPS) is the only FDA-approved oral agent for IC/BPS treatment, though evidence on effectiveness is contradictory. 1

• Clinicians must counsel patients on potential risk for macular damage and vision-related injuries before initiating or continuing PPS treatment 1
• Benefits and risks should be discussed with patients before use 1

Cimetidine (Grade B Evidence)

Cimetidine has shown clinically significant improvement of IC/BPS symptoms, pain, and nocturia with no reported adverse effects. 1

Hydroxyzine (Grade C Evidence)

Oral hydroxyzine results in clinically significant improvement compared to placebo, particularly in patients with systemic allergies. 1

• Common adverse effects: short-term sedation, weakness (generally not serious) 1

Additional Treatment Modalities

Intravesical therapies, neuromodulation, and surgical interventions are available for refractory cases. 2 These include:

• Intravesical options: dimethyl sulfoxide, lidocaine, oxybutynin, glycosaminoglycan substitution 2
• Neuromodulation: sacral and pudendal neuromodulation 2
• Cystoscopy with hydrodistension serves both diagnostic and therapeutic purposes 2

Special Consideration: Hunner Lesions

Patients with Hunner lesions should receive early cystoscopic diagnosis and treatment, as most will respond to therapy. 1 This represents a distinct phenotype requiring different management than bladder pain syndrome without Hunner lesions 3, 4

Critical Pitfalls to Avoid

• Do not perform routine cystoscopy or urodynamics on all IC/BPS patients 1
• Do not rely on pain management alone; treat underlying bladder symptoms with multimodal approach 1
• Do not prescribe chronic opioids without informed shared decision-making and periodic follow-ups to assess efficacy, adverse events, compliance, and potential abuse 1
• Do not forget to counsel patients on PPS-related macular damage risk before initiating treatment 1
• Do not expect a single treatment to work; patients typically require trials of multiple therapeutic options 1